ClinicalTrials.Veeva

Menu

Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis

T

Tanta University

Status and phase

Completed
Phase 4

Conditions

Chronic Kidney Disease-associated Pruritus
Hemodialysis
ESRD
Renal Replacement Therapy
Uremic Pruritus
End-stage Renal Disease

Treatments

Drug: Fexofenadine
Drug: Gabapentin

Study type

Interventional

Funder types

Other

Identifiers

NCT06466421
Fexof vs Gaba for UP in RHD

Details and patient eligibility

About

Several studies investigated the effectiveness of Gabapentin in Uremic Pruritus (UP). No previous studies investigated the use of fexofenadine in UP. The aim of this trial is to assess the safety and possible efficacy of fexofenadine in patients with UP.

Full description

A randomized controlled single center parallel study, that will recruit 60 participants with end stage renal disease (ESRD) on regular hemodialysis (RHD) with uremic pruritus (UP). Patients will be randomized to either Fexofenadine (60 mg orally once daily), or Gabapentin (100 mg orally after each dialysis session, "thrice weekly", with titration according to response to 100 mg orally once daily). Participants will continue treatment for 3 months.

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years old.
  • ESRD on regular hemodialysis.
  • Moderate and severe Uremic Pruritus as assessed by Visual Analogue Scale.
  • Able to provide an informed consent.

Exclusion criteria

  • Age < 18 years old.
  • Patients not on regular hemodialysis.
  • Pruritus due to other cause.
  • Cancer patients.
  • Pregnancy or breastfeeding.
  • Patients with history of substance abuse.
  • Patients with myasthenia gravis.
  • Patients who refuse or are unable to provide an informed consent.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

60 participants in 2 patient groups

Group 1: (Gabapentin group)
Active Comparator group
Description:
30 patients will receive Gabapentin 100 mg after each dialysis session (thrice weekly). Dose may be titrated after 2 weeks, according to response and tolerability, to 100 mg orally once daily for 3 months.
Treatment:
Drug: Gabapentin
Group 2: (Fexofenadine group)
Experimental group
Description:
30 patients will receive Fexofenadine 60 mg orally once daily for 3 months.
Treatment:
Drug: Fexofenadine

Trial contacts and locations

1

Loading...

Central trial contact

Mohamed I Elfalaha, PharmD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems